UCLA researchers report promising preclinical results for Allo CAR70-NKT, an off-the-shelf allogeneic cell therapy engineered to deliver a multipronged attack against metastatic renal cell carcinoma (RCC). The therapy utilizes CD70-directed CAR-engineered natural killer T cells that simultaneously target tumor cells and modulate the tumor microenvironment, demonstrating efficacy in cell lines and mouse xenograft models with a favorable safety profile. This novel approach bypasses individualized cell manufacturing delays and could broaden access to immunotherapy for RCC patients with limited treatment options.